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Bradycardia caused by interaction of venlafaxine and 
cyclosporine: A case report 
 
Abstract 
Background: Selective serotonin reuptake inhibitors (SSRIs) and serotonin-
norepinephrine reuptake inhibitors (SNRIs) are prescribed widely for the treatment of 
depression, anxiety disorders and other psychiatric disorders. Although antidepressants are 
considered as a safety drug category but unexpected cardiovascular events have been 
reported as the most serious complications. The aim of this study was to introduce a case 
presentation on bradycardia due to the drug interference of venlafaxine and cyclosporine. 
Case presentation: The patient was a 38-year old woman diagnosed with systemic lupus 
erythematosus 5 years ago, who was admitted to a general educational hospital in northern 
Iran due to intensified rheumatologic symptoms and complaining about abdominal pain. 
Cyclosporine tab were administered to the patient, 50 mg twice daily. Two weeks after the 
administration of cyclosporine, the level of blood cyclosporine was checked. The patient 
became bradycardic after starting a single dose of venlafaxine (heart rate 52 ppm). Cardiac 
assessment showed no reason for bradycardia and it subsided after a drop of venlafaxine. 
Conclusion: As a result of the potential adverse drug interactions between cyclosporine 
and antidepressants such as venlafaxine, physicians should be aware of the possibility of 
bradycardia in the simultaneous prescription of these drugs in cases. 
Keywords: Bradycardia, Venlafaxine, Cyclosporine, Serotonin-Norepinephrine reuptake 
inhibitors, Selective serotonin reuptake inhibitors. 
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Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine 
reuptake inhibitors (SNRIs) are prescribed widely for the treatment of depression, anxiety 
disorders and other psychiatric disorders (1). The cause of the widespread use of SSRIs 
and SNRIs drugs include relative safety, appropriate tolerability and low toxicity (2). 
Although antidepressants are considered as safety drugs but unexpected cardiovascular 
events such as arrhythmia or sudden heart arrest or cardiac death even in an individual 
with no history of cardiac problems have been reported as the most serious complications 
of these drugs (3, 4). SNRIs elevated norepinephrine and serotonin levels, can accelerate 
the activity of the cardiac sympathetic system and lead to a mild increase in heart rate and 
systemic blood pressure. Epidemiological studies showed that blood pressure monitoring is 
proposed for patients receiving SNRIs, especially venlafaxine. This drug with blocking 
sodium channels may show QTc wave prolongation in electrocardiogram results (5, 6). 
Even though tachycardia is more common in patients with venlafaxine, some studies 
showed bradycardia, as a result of venlafaxine consumption (7, 8). A case report has been 
reported on drug interactions resulting from the simultaneous consumption of cyclosporine 
and antidepressants such as nefazodone and venlafaxine which led to an increase in serum 
creatinine levels and increased levels of cyclosporine metabolism in the blood. Both 
nefazodone and venlafaxine led to inhibitors of CYP3A3 /4 isoenzyme (9).  
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Given the awareness of the inhibitory effects of SNRIs 
agents on hepatic cytochrome isoenzymes, it may predict the 
probability of a potential drug interaction between SNRIs 
and cyclosporine. The aim of this study was to introduce a 
case presentation on bradycardia due to the drug interference 




The patient was a 38 year old woman, married, third 
grade middle school, unemployed, diagnosed with systemic 
lupus erythematosus 5 years ago, and was admitted to a 
general educational hospital in northern Iran due to chronic 
rheumatologic symptoms and complaining about abdominal 
pain. The patient mentioned that this pain was not related to 
eating and defecation and was not exacerbated by her 
activities. The results of initial laboratory tests and 
sonography were normal.  
Cyclosporine tab 50 mg twice daily were administered to 
the patient. Two weeks after cyclosporine was prescribed, 
the blood cyclosporine level was checked. She had a history 
of treatment with sertraline, trazodone, quetiapine and 
duloxetine due to mood disorders. The patient also 
mentioned a history of suicidal attempts in the past. At that 
time, she used quetiapine 100 mg nightly. In the psychiatric 
examination, she was oriented, alert, had a dysphoric mood 
and was able to communicate well. The patient mentioned 
that she had attempted suicide twice due to marital conflicts 
but her children prevented the final action to suicide. In the 
period of her hospitalization, she had no suicidal thoughts. 
Quetiapine continued and venlafaxine was started at 37.5 mg 
per day. For 2 days, the patient received only cyclosporine, 
and had no bradycardia (figure 1) but after prescribing a 
single dose of venlafaxine, the patient became bradycardic 
(heart rate 52 ppm) (figure 2). In cardiac counseling, a 24-h 
Holter monitoring was done for the patient and the left 
ventricular ejection fraction (LVEF) was 55. Also, for 
assessment of QTc prolongation, daily electrocardiography 
(ECG) was requested 72 h later. Due to bradycardia, it was 
advised to discontinue venlafaxine and quetiapine. Also, the 
rheumatologist discontinued cyclosporine prescription. 
Psychiatric counseling was requested as a result of 
continuing psychiatric symptoms and she was visited by the 
psychiatrist twice a day for 72 h. Within 48 h of 
discontinuation (venlafaxine and cyclosporine), bradycardia 











Figure 1: The patient's ECG before prescription of 















Figure 2: The patient's ECG before prescription of 
Venlafaxine which showed bradycardia. 
 
Discussion 
In this study, the patient showed bradycardia due to 
venlafaxine. The Naranjo adverse drug reactions (ADR) 
probability scale is shown in table 1. According to the results 
of this scale, venlafaxine with a probable ADR (score 8) was 
considered as the cause of bradycardia in this patient (13). 
Venlafaxine is a relatively new and commonly prescribed 
antidepressant from the SNRIs category and it is mainly 
approved and prescribed in the case of a major depressive 
disorder and general anxiety disorder (7). Studies have 
shown that this drug causes a reuptake of both serotonin and 
norepinephrine receptors and also has a weak effect on 
histamine and alpha-adrenergic receptors (14, 15). 
According to literatures, this drug is a relatively safe agent 
and patients treated with venlafaxine compared to other 
drugs such as tricyclic antidepressants (TCAs) showed a 
lower risk of drug's interactions. Hence, it is considered as an 
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appropriate selection in the elderly or patients with 
disabilities (16) but cardiac abnormalities such as changing 
on QTc prolongation because of increased concentrations of 
venlafaxine has been reported in some cases.  These changes 
can be explained through blocking the fast current of sodium 
in ventricular myocytes (17).  
It is only contraindicated in patients with an identified 
risk of a serious cardiac ventricular arrhythmia or with 
uncontrolled hypertension. Also, it has been shown that 
compared to other effective antidepressants, venlafaxine is 
associated with the greatest risk of death from overdose (18). 
Results about this negative effect on cardiovascular system 
were controversial such that in a retrospective study, elderly 
patients who received venlafaxine were not only low to 
moderate in doses of this drug. Although there were no 
adverse cardiovascular problems, but they showed a lower 
risk of heart failure compared to SSRIs drugs such as 
sertraline (19). 
 
Table 1: The Naranjo adverse drug reaction probability scale: To assess the adverse drug reaction. 
 Yes No Don’t  
 Know 
Score 
1.Are there previous conclusive report on this reaction ✔   +1 
2. Did the adverse event occur after the suspected drug was administered? ✔   +2 
3. Did the adverse reaction improve when the drug was continued or a specific antagonist was 
administered? 
 ✔  0 
4. Did the adverse reaction reappear when the drug was readministered?   ✔ 0 
5. Are there alternative causes (other than the drug) that could have on their own caused the 
reaction? 
 ✔  +2 
6. Did the reaction reappear when a placebo was given?   ✔ 0 
7. Was the blood detected in the blood (or other fluids) in concentrations known to be toxic?  ✔  +1 
8. Was the reaction more severe when the dose was increased or less severe when the dose was 
decreased? 
✔   +1 
9. Did the patient have a similar reaction to the same or similar drugs in any previous exposure?   ✔ 0 
10. Was the adverse events confirmed by any objective evidence? ✔   +1 
 
Cyclosporine is an immunosuppressive agent which is 
used as a proper drug for the treatment of many autoimmune 
diseases (20). In a case report study in which the patient 
underwent allogeneic hematopoietic stem cell 
transplantation, cyclosporine 60 mg/kg was administered for 
two days and after continuous infusion of cyclosporine, 
3mg/kg was prescribed with maintained checking of 
cyclosporine serum between 250-400 ng/dl. On day 23, 
serum cyclosporine increased to 450 ng/dl, heart rate 
decreased to 30-40/min and ECG showed sinus bradycardia. 
This study showed that there was a significant relationship 
between the dose of cyclosporine used and the occurrence of 
bradycardia in the patient (21).  
Two probable mechanisms for bradycardia were 
considered as induced by the use of cyclosporine. In the first 
proposed mechanism, Cyclosporine may suppress the sinus 
node automatically and sinus bradycardia was reported in 
cases with cyclosporine prescription but this abnormality in  
 
the sinus node diminished after discontinuation of this drug  
 
(22). The second possible mechanism is that cyclosporine 
may lead to bradycardia by provoking the parasympathetic 
nervous system but studies have suggested that the second 
possible mechanism is less likely (21, 23).  
A study which assessed the adverse effect of 
cyclosporine on baroreflexes through the inhibition of 
testosterone receptors of cardiac vagal control showed that 
short term cyclosporine treatment led to decreased plasma 
testosterone level, impaired baroreflexes function, reduced 
its sensitivity and overall caused to reflex bradycardia (23). 
The selection of antidepressants depends on many factors 
such as the current drug prescribed for the patient, and the 
probable drugs interactions. Most antidepressants are 
metabolized in the liver through the isoenzyme P450 
cytochrome system. The inhibition of this isoenzyme by 
drugs affect other drugs which need an isoenzyme for 
metabolism or transformation (14).  
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Among the various isoenzymes of P450, CYP3A3/4, 
plays the most important role in the metabolism of 
cyclosporine and inhibition of this system leads to decreased 
cyclosporine metabolism and increased cyclosporine level 
which cause toxicity in patients. Venlafaxine and nefazodone 
have the strongest inhibitory action on the CYP3A3/4 
isoenzyme and decreased cyclosporine metabolism (9, 16). 
In this case report, maybe venlafaxine and cyclosporine drug 
interaction caused bradycardia but it was not specifically 
clear that which drugs creates bradycardia. Because patient 
showed no bradycardia during drug consumption of 
cyclosporine and after adding a single dose of venlafaxine 
patient showed bradycardia in her ECG and also bradycardia 
disappeared after discontinuation of venlafaxine, it is 
probably attributed to single dose of venlafaxine. Clinical 
studies have shown that the adverse interactions of these 
drugs depend on many factors such as the concentration of 
the isoenzyme inhibitor, amount of participation of active 
metabolites in the isoenzyme inhibitory activity and the level 
of toxicity of prescribed drugs (9). As a result of the 
potential adverse drug interactions between cyclosporine and 
antidepressants such as venlafaxine, physicians should be 
aware of the possibility of bradycardia in simultaneous 
prescription of these drugs in cases. Also, it has been 
proposed that ECG control should be continued during 
therapy, especially in patients with cardiovascular 
abnormalities or disorders.  
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